A federal judge has approved multiple classes in litigation accusing Indian generic drugmaker Ranbaxy Laboratories of delaying the launch of generic drugs by submitting false applications to US regulators.
In an opinion issued Friday, May 14, US District Judge Nathaniel Gorton in Boston certified classes of both direct purchasers, including drug wholesalers, and indirect purchasers, such as health plans and insurance companies.
“We look forward to trial in January 2022,” said Thomas Sobol of Hagens Berman Sobol Shapiro, a lawyer for the direct purchasers.
India’s Sun Pharmaceutical Industries, which acquired Ranbaxy in 2014, and Devora Allon of Kirkland & Ellis, a lawyer for Ranbaxy, did not immediately respond to requests for comment. Nor did Gerald Lawrence of Lowey Dannenberg, a lawyer for the indirect purchasers.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
